Subcutaneous fat necrosis of the newborn: hypercalcaemia with hepatic and atrial myocardial calcification
- 1Department of Paediatrics, Divisions of Neonatology and Paediatric Cardiology, Leiden University Medical Center, Leiden, The Netherlands
- 2Department of Paediatrics, Reinier de Graaf Gasthuis, Delft, The Netherlands
- Correspondence to:
Dr Walther, Department of Paediatrics, Division of Neonatology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands;
- Accepted 26 September 2002
Subcutaneous fat necrosis of the newborn (SCFN) is a very rare disorder, which can be complicated by hypercalcaemia and thrombocytopenia. The case is presented of an infant with SCFN and symptomatic hypercalcaemia, who developed calcifications in the liver, the inferior vena cava, and the atrial septum of the heart. The hypercalcaemia was treated with hyperhydration, frusemide, glucocorticoids, and a diet low in calcium and vitamin D. Clinical features, diagnosis, complications, and treatment of this rare condition are discussed.
Subcutaneous fat necrosis of the newborn (SCFN) is a rare condition of unknown pathophysiology, characterised by erythematous to violaceous, firm, and painful subcutaneous nodules. The skin lesions are mainly found on the face, trunk, buttocks, and proximal extremities and appear soon after birth up to four weeks after delivery. Normally SCFN is a self limiting condition in which the skin lesions resolve spontaneously within weeks to months.1,2 Hypercalcaemia is a complication of SCFN, which can be life threatening if not treated adequately.3–8
A female infant was delivered full term by caesarean section because of fetal distress. The pregnancy had been uncomplicated, except that the mother was admitted two days before the delivery because of an accidental fall. The birth weight was 3100 g. Apgar scores were 3, 7, and 8 at one, five, and 10 minutes. The baby was intubated and placed on mechanical ventilation for respiratory failure. The cord arterial pH was 6.85 and the base deficit 18.1 mmol/l. Blood cultures were drawn, and the infant received amoxicillin and gentamicin. A chest radiograph showed cardiac enlargement with clear lung fields. Echocardiography showed pulmonary hypertension with right to left shunting across the patent foramen ovale and ductus arteriosus. After 24 hours, mechanical ventilation could be discontinued, and the respiratory failure after birth was ascribed to persistent pulmonary hypertension following birth asphyxia. Blood cultures remained negative.
On the third day, the infant developed a red, painful, nodular swelling on her back with a diameter of 5 cm, suggestive of a bacterial skin infection. Laboratory investigation included: haemoglobin, 152 g/l; platelets, 56 × 109/l; white blood cells, 13 × 109/l; normal coagulation. Total calcium level was 2.8 mmol/l (normal range 2.1–2.6 mmol/l), ionised calcium level was 1.55 mmol/l (normal range 1.0–1.4 mmol/l), and 1,25-hydroxyvitamin D concentration was 160 pmol/l (normal range 40–140 pmol/l). Parathyroid hormone level was < 1.0 pmol/l, and parathyroid-like protein level was < 0.1 pmol/l. Serum calcium levels continued to increase progressively (maximum value 3.5 mmol/l on day 30), despite treatment with hydration (180 ml/kg/day) and frusemide (2 mg/kg/day). The hypercalcaemia became symptomatic, with vomiting, anorexia, and agitation. Because the skin lesions became more painful, first acetaminophen and later morphine (0.02 mg/kg/h) were administered. The hypercalcaemia and skin lesions started to resolve after treatment with prednisone (2 mg/kg/day) and a milk formula low in calcium and vitamin D (Basic CaD; Milupa, Friedrichshof, Germany). Within five days, total and ionised calcium levels normalised (day 35). Corticosteroid treatment was discontinued after one week, and the special milk formula and diuretics after one month.
A repeat echocardiogram depicted an echodense lesion in the atrial septum (fig 1), which was diagnosed as calcification on a computed tomographic scan (fig 2). Calcifications were also seen in the inferior vena cava and liver (fig 3).
Follow up by the family doctor showed normal physical and neurological development. A repeat echocardiogram and computed tomographic scan were declined by the parents.
SCFN is a rare, often painful condition of unknown pathophysiology. It usually occurs in the first week of life following a complicated delivery and is characterised by very painful, firm, indurated, erythematous nodules and plaques over the buttocks, trunk, arms, and cheeks. Newborns who develop SCFN are usually healthy and full term at delivery, but have had some obstetric trauma, meconium aspiration, asphyxia, hypothermia, or hypoxaemia. Owing to its benign, self limiting course, SCFN is thought to be underdiagnosed, and its incidence is unknown. No racial or sex preference has been reported.
The cause and pathogenesis of SCFN are not known. It has been postulated that cold or stress induced injury to immature fat, resulting in necrosis and the development of a granulomatous infiltrate, may play a role in initiating the process.9 Various mechanisms for the development of the necrosis have been proposed: (a) an underlying defect in neonatal fat metabolism, resulting in an increase in saturated fatty acids within the subcutaneous tissue, which, exacerbated by neonatal stress, may precipitate this condition4; (b) fat necrosis caused by local trauma during delivery4; (c) hypothermia causing the neonatal fat, which is composed of saturated fatty acids with a relatively high melting point, to crystallise.9,10 The areas of fat necrosis seldom progress to atrophy, scarring, or ulceration.
SCFN is a harmless, self limiting condition, but appreciable morbidity and mortality can result from the associated hypercalcaemia, the pathogenesis of which is not known.3–8 Potential causes include increased prostaglandin activity leading to osteoclast activation, calcium release from necrotic fat cells, and increased production of 1,25-dihydroxyvitamin D by macrophages, leading to increased bone turnover.11–13 The incidence of hypercalcaemia as a complication is uncertain. If mild hypercalcaemia is present, symptoms may be absent, or the child may display irritability, weight loss, apathy, or hypotonia.
Another known complication of SCFN is thrombocytopenia. It is postulated that the thrombocytopenia in newborns with SCFN may reflect local sequestration within the subcutaneous tissue.14 Increased levels of prostaglandin E have been reported in SCFN.15 When prostaglandin E is used therapeutically in newborns, thrombocytopenia is a known side effect. We postulate that there may be an association between the raised prostaglandin E levels and the thrombocytopenia in SCFN.
The tendency for calcification to occur in the atrial septum, inferior vena cava, and liver in this case is interesting, and has to our knowledge not previously been reported. It seems reasonable to assume that the hypercalcaemia and calcification are related. Well known causes of calcification, such as occur in atheromatous plaques or in neonatal hearts with systemic lupus erythematosis, do not appear to play a part. Congenital causes of soft tissue calcification can also be excluded because calcification of the atrial septum was not seen at the initial echocardiographic examination. The seven cases of massive myocardial calcification in the perinatal period reported by Drut et al16 have myocardial damage in common, although atrial myocardial calcification was not seen. In our case, perinatal asphyxia may have caused myocardial damage, but we have no proof of this. The initial echocardiographic findings depicted evidence of pulmonary hypertension, but not of depressed ventricular function. The massive myocardial calcification may represent the human counterpart of so called dystrophic cardiac calcinosis, a genetic disorder in mice.
When hypercalcaemia occurs, the first line of treatment is hyperhydration and calcium wasting diuretics (such as frusemide) and a milk formula with low calcium and vitamin D content.4,7 Prednisone is used when these measures fail. Glucocorticoids interfere with the metabolism of vitamin D to its active form (1,25-hydroxyvitamin D) and also inhibit the production of 1,25-hydroxyvitamin D by the macrophages involved in the inflammatory process.10–12 Short term etidronate (bisphoshonate) treatment has been used successfully to control hypercalcaemia by reducing bone resorption,7 but whether the cause of hypercalcaemia in SCFN is due to enhanced bone resorption has been questioned.17 As the serum calcium levels can be elevated for months, even after recovery from fat necrosis, serum calcium levels should be checked periodically.
Although SCFN and hypercalcaemia are rare complications in neonates with perinatal problems, the sequelae of hypercalcaemia can be life threatening. A neonate who develops skin lesions consistent with SCFN should therefore be followed for the possible onset of hypercalcaemia.
Thanks go to Dr Tjong a Lieng from the Radiology Department at the LUMC for assistance with computed tomography.